July 13, 2018
by inesp.alves
4 Comments
TherAchon is a Biotechnology company that was established in 2014 and focuses on rare diseases. It is developing a drug for achondroplasia in particular: TA-46, which is planned to go onto phase I clinical trials in 2019 [1]. In order to … Continue reading
May 4, 2018
by inesp.alves
0 comments
Obesity and metabolism are important topics related to achondroplasia but rarely discussed. Developed especially during childhood, obesity is a common complication associated with achondroplasia, affecting more than 50% of people with this condition. The extra weight exacerbates many other complications … Continue reading
February 14, 2018
by inesp.alves
2 Comments
Therachon announced today, 14 February 2018, the beginning of Phase 1 for the clinical trial with TA-46 for achondroplasia. This trial will take place in The Netherlands, with 70 adult healthy volunteers and it will be: randomized – A study in which … Continue reading
June 25, 2017
by inesp.alves
6 Comments
Therachon’s medicine in development for achondroplasia, TA-46, was granted Orphan Drug designation by the medicine agencies FDA and EMA. TA-46 is a type 3 fibroblast growth factor receptor antagonist addressing achondroplasia. This medicine is an inactive form of the receptor that … Continue reading
January 5, 2017
by inesp.alves
5 Comments
A press release from Business Wire stated that Therachon AG, a biotechnology company focused on rare genetic diseases, announced today it has appointed Luca Santarelli, M.D., as Chief Executive Officer and Director, and raised more $5 million for new medicines R&D (research a … Continue reading